Amarin Corporation arrives at this week's note in the middle of a live earnings event, with Q1 results landing this morning and the market still processing a mixed beat-and-miss print.
The earnings picture today is split. Revenue came in at $45.1M, beating the $43.8M consensus estimate — a meaningful top-line beat driven by the company's partner-led growth strategy. On the bottom line, however, the quarter disappointed: EPS missed by $0.21, a notable shortfall. Amarin's EBITDA remains negative at around -$25.6M, though net income swung to approximately $34.2M on a reported basis, and the company carries a net cash position of roughly $174M — a meaningful buffer for a small-cap biotech. The stock entered the session at $13.96, off 3.8% on the week and 3.4% over the past month, leaving it modestly under pressure heading into the print.
The most striking divergence this week sits in options. Positioning has turned decisively call-heavy — the put/call ratio collapsed to 0.11, running almost two full standard deviations below its 20-day average of 0.20. That is one of the most bullish options readings of the past year, near the 52-week low of 0.04 for the PCR. Traders were leaning aggressively long via calls before the results were released, suggesting the market anticipated a positive catalyst. Short interest, meanwhile, tells a quieter story. At 2.2% of free float, it barely registers as a meaningful bear position — shares shorted ticked up roughly 4% on the day but are flat over the week. Borrowing the stock remains very cheap at 0.51% annually, and availability in the lending market is ample, with the 52-week peak utilization of only 54% confirming this has never been a contested borrow. The ORTEX short score of 51.5, sitting in the middle of its 10-day range, adds nothing alarming to the picture.
The positioning picture, then, is not one of crowded shorts and squeeze potential — it is one of options traders betting on a catalyst while the short-selling community stays mostly on the sidelines. That call-side enthusiasm preceded a revenue beat but an EPS miss: a classic mixed quarter that tends to create intraday volatility as the two signals offset each other. The one prior earnings event in the dataset — the March 2026 print — saw the stock fall 3.3% on the day before recovering 12.6% over the following five sessions. That pattern of an initial dip followed by a recovery may be worth watching given today's similarly ambiguous print, though today's setup carries its own context.
Institutional ownership is thin and concentrated. Sarissa Capital Management holds nearly 8% of shares outstanding, making it by far the largest institutional presence. They added 430,000 shares in the most recent reporting period — a committed, activist-style position. Acadian Asset Management built a new stake of 580,000 shares. Insider activity this week was purely administrative: board members received small equity awards on April 17 and immediately sold a nominal 403 shares each at $14.98 under a structured plan. Net insider activity over 90 days is a small positive at roughly $145,000 in value, carrying no signal worth reading into.
What to watch now is whether the revenue beat or the EPS miss dominates the post-earnings narrative — and whether the sharp call-side positioning from the past week gets unwound or validated by the stock's reaction through this week's close.
See the live data behind this article on ORTEX.
Open AMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
